News
PYCXF
1.500
NaN%
--
Bell Potter Sticks to Their Buy Rating for PYC Therapeutics Limited (PYC)
TipRanks · 3h ago
Index Rebalance Adds PYC Therapeutics to S&P/ASX 300
TipRanks · 09/04 08:07
Ord Minnett Keeps Their Buy Rating on PYC Therapeutics Limited (PYC)
TipRanks · 09/04 05:55
PYC Therapeutics Updates Investors, Emphasizes Early-Stage Status and Risks
TipRanks · 09/03 23:01
PYC Therapeutics to Showcase ADOA Drug Data at NOSA 2026
TipRanks · 09/02 23:05
Retail Employees Super Fund Exits Substantial Holding in PYC Therapeutics
TipRanks · 09/02 06:15
PYC Therapeutics Reports Positive Early Safety Data for PKD Drug PYC-003
TipRanks · 08/30 23:27
PYC details evolving governance framework aligned with ASX principles
TipRanks · 08/28 09:28
PYC Therapeutics Details Governance and Operations in 2026 Annual Report
TipRanks · 08/28 09:28
PYC Therapeutics Narrows Loss and Strengthens Balance Sheet in FY2026
TipRanks · 08/28 09:27
PYC Therapeutics Schedules September Investor Webinar to Detail Pipeline Progress
TipRanks · 08/17 22:49
PYC Therapeutics boosts CEO equity incentives with major option and rights grants
TipRanks · 08/14 01:48
PYC Therapeutics Earns Buy Rating on Strong Early Safety Profile and Dose Escalation Support for PYC-003 in ADPKD
TipRanks · 08/06 08:36
Bell Potter Sticks to Its Buy Rating for PYC Therapeutics Limited (PYC)
TipRanks · 07/30 09:07
PYC Therapeutics advances genetic disease pipeline and strengthens corporate footing
TipRanks · 07/28 23:29
PYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial
TipRanks · 07/21 22:54
PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting
TipRanks · 07/15 08:27
PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates
TipRanks · 07/07 23:18
PYC Therapeutics Strengthens Financial Leadership with New CFO Appointment
TipRanks · 07/06 22:54
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
TipRanks · 06/17 23:25
More
Webull provides a variety of real-time PYCXF stock news. You can receive the latest news about PYC Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PYCXF
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).